NanoViricides, Inc. (NYSE American: NNVC) reported its fiscal year 2026 results, revealing key regulatory and clinical advancements for its broad-spectrum antiviral candidate NV-387. The company received regulatory approval in the Democratic Republic of Congo to initiate Phase II trials evaluating NV-387 Oral Gummies for the treatment of Mpox and Ebola, with both trials beginning enrollment at the end of September 2026. Additionally, the U.S. Food and Drug Administration granted Orphan Drug Designation and Rare Pediatric Disease Drug designation for NV-387 as a treatment for measles. These developments underscore the potential of NV-387 to address multiple high-consequence viral diseases.
The approval for Phase II trials in the DRC represents a critical step forward for NanoViricides, as it moves its lead candidate into human testing for indications with significant unmet medical need. The trials will assess the safety and efficacy of NV-387 Oral Gummies, a formulation designed for ease of administration in outbreak settings. The FDA designations for measles provide further validation of NV-387's broad-spectrum antiviral potential and may expedite its development path. For investors, these milestones signal tangible progress in a clinical-stage biotech, where regulatory achievements often drive valuation and partnership opportunities.
Financially, NanoViricides reported approximately $2.79 million in cash and cash equivalents as of June 30, 2026, up from approximately $1.67 million a year earlier. The company raised approximately $9.01 million through registered direct and at-the-market equity offerings during fiscal 2026, and subsequently raised approximately $3.8 million in July. It is pursuing additional funding through grants and contracts, partnerships, debt or equity financing to support ongoing clinical programs. This capital raise reflects investor confidence and provides necessary resources to advance NV-387 through Phase II trials.
NanoViricides is a clinical-stage company creating special-purpose nanomaterials for antiviral therapy. Its novel nanoviricide class of drug candidates is based on intellectual property and technology from TheraCour Pharma, Inc. The company's business model involves licensing technology for specific application verticals, and its lead drug candidate NV-387 is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and measles. Another advanced candidate, NV-HHV-1, targets Shingles. For more details on the company's pipeline, visit www.nanoviricides.com.
The broader implications of these announcements are significant. If NV-387 proves effective in Phase II trials, it could become a first-in-class broad-spectrum antiviral, potentially transforming treatment paradigms for viral outbreaks. The DRC trials for Mpox and Ebola are particularly noteworthy given the recurring outbreaks in Africa and the limited therapeutic options available. Success could lead to rapid deployment in affected regions and attract global health interest. Moreover, the FDA designations for measles highlight the drug's versatility and may open doors to additional indications. For the biotech sector, NanoViricides' progress demonstrates the potential of nanomedicine platforms to address a wide range of viruses.
To stay updated on NanoViricides' developments, visit the company's newsroom at https://ibn.fm/NNVC. The full press release can be accessed at https://ibn.fm/s000r. For more information on MissionIR, a specialized communications platform, visit MissionIR. MissionIR is part of the Dynamic Brand Portfolio at IBN, which offers corporate communications solutions and social media distribution. Please review the full terms of use and disclaimers at https://www.MissionIR.com/Disclaimer.
